Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.

2022-09

Wight, Joel C

Hamad, Nada

Campbell, Belinda A

Ku, Matthew

Lee, Kenneth

Rose, Hannah

Armytage, Tasman

Latimer, Maya

Lee, Hui-Peng

Lee, Sze Ting

Dickinson, Michael

Khor, Richard

Verner, Emma

diagnosis

diffuse large B-cell lymphoma

management

prognosis

Journal Article

https://orcid.org/0000-0002-3216-2392

https://orcid.org/0000-0001-7929-1450

https://orcid.org/0000-0002-9289-1335

https://orcid.org/0000-0001-8641-456X

https://orcid.org/0000-0002-1492-5966

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

10.1111/imj.15533

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Although aggressive, cure is achievable in approximately 60% of cases with primary chemoimmunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, central nervous system prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.

link

Internal medicine journal 2022; 52(9): 1609-1623

Internal medicine journal